OBJECTIVE: Inflammatory activation of valve endothelium is an early phase of aortic valve disease pathogenesis, but subsequent mechanisms are poorly understood. Adult valve endothelial cells retain the developmental ability to undergo endothelial-to-mesenchymal transformation (EndMT), but a biological role has not been established. Here, we test whether and how inflammatory cytokines (tumor necrosis factor-α and interleukin-6) regulate EndMT in embryonic and adult valve endothelium. METHODS AND RESULTS: Using in vitro 3-dimensional collagen gel culture assays with primary cells, we determined that interleukin-6 and tumor necrosis factor-α induce EndMT and cell invasion in dose-dependent manners. Inflammatory-EndMT occurred through an Akt/nuclear factor-κB-dependent pathway in both adult and embryonic stages. In embryonic valves, inflammatory-EndMT required canonical transforming growth factor-β signaling through activin receptor-like kinases 2 and 5 to drive EndMT. In adult valve endothelium, however, inflammatory-induced EndMT still occurred when activin receptor-like kinases 2 and 5 signaling was blocked. Inflammatory receptor gene expression was significantly upregulated in vivo during embryonic valve maturation. Endothelial-derived mesenchymal cells expressing activated nuclear factor-κB were found distal to calcific lesions in diseased human aortic valves. CONCLUSIONS: Inflammatory cytokine-induced EndMT in valve endothelium is present in both embryonic and adult stages, acting through Akt/nuclear factor-κB, but differently using transforming growth factor-β signaling. Molecular signatures of valve EndMT may be important diagnostic and therapeutic targets in early valve disease.
OBJECTIVE: Inflammatory activation of valve endothelium is an early phase of aortic valve disease pathogenesis, but subsequent mechanisms are poorly understood. Adult valve endothelial cells retain the developmental ability to undergo endothelial-to-mesenchymal transformation (EndMT), but a biological role has not been established. Here, we test whether and how inflammatory cytokines (tumor necrosis factor-α and interleukin-6) regulate EndMT in embryonic and adult valve endothelium. METHODS AND RESULTS: Using in vitro 3-dimensional collagen gel culture assays with primary cells, we determined that interleukin-6 and tumor necrosis factor-α induce EndMT and cell invasion in dose-dependent manners. Inflammatory-EndMT occurred through an Akt/nuclear factor-κB-dependent pathway in both adult and embryonic stages. In embryonic valves, inflammatory-EndMT required canonical transforming growth factor-β signaling through activin receptor-like kinases 2 and 5 to drive EndMT. In adult valve endothelium, however, inflammatory-induced EndMT still occurred when activin receptor-like kinases 2 and 5 signaling was blocked. Inflammatory receptor gene expression was significantly upregulated in vivo during embryonic valve maturation. Endothelial-derived mesenchymal cells expressing activated nuclear factor-κB were found distal to calcific lesions in diseased human aortic valves. CONCLUSIONS: Inflammatory cytokine-induced EndMT in valve endothelium is present in both embryonic and adult stages, acting through Akt/nuclear factor-κB, but differently using transforming growth factor-β signaling. Molecular signatures of valve EndMT may be important diagnostic and therapeutic targets in early valve disease.
Authors: R Saeid Farivar; Lawrence H Cohn; Edward G Soltesz; Tomislav Mihaljevic; James D Rawn; John G Byrne Journal: Eur J Cardiothorac Surg Date: 2003-10 Impact factor: 4.191
Authors: S Hernández-Gutierrez; I García-Peláez; A Zentella-Dehesa; M Ramos-Kuri; P Hernández-Franco; F Hernández-Sánchez; E Rojas Journal: Apoptosis Date: 2006-07 Impact factor: 4.677
Authors: Jesper Hjortnaes; Jonathan Butcher; Jose-Luiz Figueiredo; Mark Riccio; Rainer H Kohler; Kenneth M Kozloff; Ralph Weissleder; Elena Aikawa Journal: Eur Heart J Date: 2010-07-02 Impact factor: 29.983
Authors: Robert A Levine; Albert A Hagége; Daniel P Judge; Muralidhar Padala; Jacob P Dal-Bianco; Elena Aikawa; Jonathan Beaudoin; Joyce Bischoff; Nabila Bouatia-Naji; Patrick Bruneval; Jonathan T Butcher; Alain Carpentier; Miguel Chaput; Adrian H Chester; Catherine Clusel; Francesca N Delling; Harry C Dietz; Christian Dina; Ronen Durst; Leticia Fernandez-Friera; Mark D Handschumacher; Morten O Jensen; Xavier P Jeunemaitre; Hervé Le Marec; Thierry Le Tourneau; Roger R Markwald; Jean Mérot; Emmanuel Messas; David P Milan; Tui Neri; Russell A Norris; David Peal; Maelle Perrocheau; Vincent Probst; Michael Pucéat; Nadia Rosenthal; Jorge Solis; Jean-Jacques Schott; Ehud Schwammenthal; Susan A Slaugenhaupt; Jae-Kwan Song; Magdi H Yacoub Journal: Nat Rev Cardiol Date: 2015-10-20 Impact factor: 32.419
Authors: Yong-Ung Lee; Juan de Dios Ruiz-Rosado; Nathan Mahler; Cameron A Best; Shuhei Tara; Tai Yi; Toshihiro Shoji; Tadahisa Sugiura; Avione Y Lee; Frank Robledo-Avila; Narutoshi Hibino; Jordan S Pober; Toshiharu Shinoka; Santiago Partida-Sanchez; Christopher K Breuer Journal: FASEB J Date: 2016-04-08 Impact factor: 5.191
Authors: Ming He; Zhen Chen; Marcy Martin; Jin Zhang; Panjamaporn Sangwung; Brian Woo; Adriana H Tremoulet; Chisato Shimizu; Mukesh K Jain; Jane C Burns; John Y-J Shyy Journal: Circ Res Date: 2016-12-06 Impact factor: 17.367
Authors: Philipp E Bartko; Jacob P Dal-Bianco; J Luis Guerrero; Jonathan Beaudoin; Catherine Szymanski; Dae-Hee Kim; Margo M Seybolt; Mark D Handschumacher; Suzanne Sullivan; Michael L Garcia; James S Titus; Jill Wylie-Sears; Whitney S Irvin; Emmanuel Messas; Albert A Hagège; Alain Carpentier; Elena Aikawa; Joyce Bischoff; Robert A Levine Journal: J Am Coll Cardiol Date: 2017-09-05 Impact factor: 24.094